Summit Therapeutics (NASDAQ:SMMT) is one of the 17 biotechnology stocks with more than 50% upside. As of the close of play on February 12, consensus sentiment around Summit Therapeutics (NASDAQ:SMMT) was moderately bullish. The stock had received coverage from 6 analysts, 4 of whom had assigned Buy ratings and 2 gave Hold calls. With no Sell rating, the stock carries a projected median 1-year price target of $57.98, implying a strong upside of more than 296%. Adaptive Biotechnologies (ADPT) Hits 3-Year H ...

Legend Biotech (NASDAQ:LEGN) is one of the 17 biotechnology stocks with more than 50% upside. On January 20, Leonid Timashev of RBC Capital maintained an Outperform rating on Legend Biotech (NASDAQ:LEGN) and set a $66 price target. The analyst shed light on the FDA’s draft guidance that supports the use of Minimal Residual Disease (MRD) negativity and complete response rate to expedite approval endpoints in multiple myeloma. This appears favorable for Legend Biotech (LEGN), as it supports the company’s tr ...

Soleno Therapeutics (NASDAQ:SLNO) is one of the 17 biotechnology stocks with more than 50% upside. On January 20, the price target on Soleno Therapeutics (NASDAQ:SLNO) was increased from $110 to $120 by Ram Selvaraju from H.C. Wainwright. He also reaffirmed his Buy rating on the stock, which, as per his forecasts, offers an upside potential of almost 211%. The analyst based his rating on the company’s impressive sales figures, which continue to beat estimates. Likoper/Shutterstock.com On January 20, We ...

Corcept Therapeutics (NASDAQ:CORT) is one of the 17 biotechnology stocks with more than 50% upside. On February 2, Edward Nash from Canaccord Genuity reaffirmed his Buy rating for Corcept Therapeutics (NASDAQ:CORT). He forecasted a price target of $100, which leads to almost 161% upside potential on the stock. Nestor Rizhniak/Shutterstock.com Nash noted that the CRL issued by the U.S. FDA for the relacorilant NDA confirms their prior expectations. Their model already accounted for the need to conduct a ...

Ultragenyx Pharmaceutical (NASDAQ:RARE) is one of the 17 biotechnology stocks with more than 50% upside. On February 3, the price target on Ultragenyx Pharmaceutical (NASDAQ:RARE) was set to $60 by H.C. Wainwright analyst Ram Selvaraju, who maintained a Buy rating on the stock. The analyst’s estimate leads to a promising upside potential of more than 155% from the prevailing level. Adaptive Biotechnologies (ADPT) Hits 3-Year High. Here's Why Pressmaster/Shutterstock.com Selvaraju attributed his views t ...

Wave Life Sciences (NASDAQ:WVE) is one of the 17 biotechnology stocks with more than 50% upside. As of the February 12 closing, consensus sentiment around Wave Life Sciences (NASDAQ:WVE) remained strongly bullish. The stock received coverage from 15 analysts, all of whom assigned Buy ratings. The stock has a projected median 1-year price target of $32.57, implying more than 154% upside. 10x Genomics Expands Flex Lineup with High-Throughput Single-Cell Assay Launch Pressmaster/Shutterstock.com On Februa ...

Dyne Therapeutics (NASDAQ:DYN) is one of the 17 biotechnology stocks with more than 50% upside. As of the February 12 closing, Dyne Therapeutics (NASDAQ:DYN) held a strongly bullish consensus view. Of the 9 analysts covering the stock, 7 assigned Buy ratings and 2 issued Hold ratings. With no Sell rating, the stock has a projected median 1-year price target of $39.33, implying almost 146% upside. Billion Photos/Shutterstock.com On January 20, Dyne Therapeutics (DYN) reported that Japan’s Ministry of He ...

Vaxcyte Incorporated (NASDAQ:PCVX) is one of the 17 biotechnology stocks with more than 50% upside. On January 23, Cantor Fitzgerald maintained its Overweight rating on Vaxcyte Incorporated (NASDAQ:PCVX), highlighting continued progress across the company’s clinical pipeline. The firm reflected on the topline readout from the Phase 3 OPUS-1 trial, expected in the fourth quarter of 2026, with a planned BLA filing the following year. OPUS-2 has already begun participant dosages, and OPUS-3 is set to start i ...

Core Viewpoint - Olema Pharmaceuticals (NASDAQ:OLMA) is identified as a promising investment opportunity with significant upside potential, particularly in the biotechnology sector focused on women's cancers [1][2]. Group 1: Company Overview - Olema Pharmaceuticals is a clinical-stage biopharmaceutical company dedicated to developing therapies for women's cancers, specifically targeting ER+/HER2- breast cancer [3]. - The company's lead program, Palazestrant (OP-1250), is currently in Phase 3 clinical trials aimed at treating metastatic breast cancer [3]. Group 2: Market Potential - The peak sales for Palazestrant are projected to reach $3.1 billion by 2035, indicating substantial future revenue potential [2]. - The global market opportunity for endocrine therapy in ER+HER2 is estimated to exceed $20 billion, suggesting ample space for multiple major players in the market [2]. Group 3: Analyst Ratings - Laura Prendergast from Stifel Nicolaus initiated coverage of Olema Pharmaceuticals with a Buy rating and a price target of $48, indicating over 102% upside potential for investors [1]. - Michael Yee from UBS also assigned a Buy rating with the same price target of $48, citing a more favorable outlook for the biotech segment following a challenging period [2].

Beam Therapeutics (NASDAQ:BEAM) is one of the 17 biotechnology stocks with more than 50% upside. On January 22, Patrick Trucchio from H.C. Wainwright maintained a Buy rating on Beam Therapeutics (NASDAQ:BEAM), with a price target of $80. This results in a highly attractive upside potential of more than 197%. Looker_Studio/Shutterstock.com Trucchio’s rating is based on several factors linked with the company’s clinical and regulatory progress. He noted the company’s recent agreement with the U.S. FDA to ...